Topical Treatment with Xiaozheng Zhitong Paste (XZP) Alleviates Bone Destruction and Bone Cancer Pain in a Rat Model of Prostate Cancer-Induced Bone Pain by Modulating the RANKL/RANK/OPG Signaling.
Autor: | Yanju Bao, Yebo Gao, Maobo Du, Wei Hou, Liping Yang, Xiangying Kong, Honggang Zheng, Weidong Li, Baojin Hua |
---|---|
Předmět: |
ANALYSIS of variance
ANIMAL experimentation BIOLOGICAL models CANCER pain ENZYME-linked immunosorbent assay GENES HERBAL medicine HIGH performance liquid chromatography CHINESE medicine PLACEBOS POLYMERASE chain reaction PROSTATE tumors RATS RESEARCH funding CUTANEOUS therapeutics TIBIA TUMOR necrosis factors WESTERN immunoblotting X-rays REPEATED measures design REVERSE transcriptase polymerase chain reaction DATA analysis software OSTEOBLASTS ONE-way analysis of variance DRUG administration DRUG dosage |
Zdroj: | Evidence-based Complementary & Alternative Medicine (eCAM); 2015, p1-14, 14p, 1 Black and White Photograph, 3 Charts, 5 Graphs |
Abstrakt: | To explore the effects and mechanisms of Xiaozheng Zhitong Paste (XZP) on bone cancer pain, Wistar rats were inoculated with vehicle or prostate cancer PC-3 into the tibia bone and treated topically with inert paste, XZP at 15.75, 31.5, or 63 g/kg twice per day for 21 days. Their bone structural damage, nociceptive behaviors, bone osteoclast and osteoblast activity, and the levels of OPG, RANL, RNAK, PTHrP, IGF-1, M-CSF, IL-8, and TNF-a were examined. In comparison with that in the placebo group, significantly reduced numbers of invaded cancer cells, decreased levels of bone damage and mechanical threshold and paw withdrawal latency, lower levels of serum TRACP5b, ICTP, PINP, and BAP, and less levels of bone osteoblast and osteoclast activity were detected in the XZP-treated rats (P < 0.05). Moreover, significantly increased levels of bone OPG but significantly decreased levels of RANL, RNAK, PTHrP, IGF-1, M-CSF, IL-8, and TNF-a were detected in the XZP-treated rats (P < 0.05 for all). Together, XZP treatment significantly mitigated the cancer-induced bone damage and bone osteoclast and osteoblast activity and alleviated prostate cancer-induced bone pain by modulating the RANKL/RANK/OPG pathway and bone cancer-related inflammation in rats. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |